BRIEF published on 04/10/2025 at 19:05, 1 year 2 months ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 2 months ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 1 year 4 months ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 1 year 4 months ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 1 year 4 months ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 4 months ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 1 year 5 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/04/2024 at 19:55, 1 year 6 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 6 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 6 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
Published on 06/20/2026 at 01:00, 1 day 2 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 3 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 22 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 1 hour ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 2 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 5 hours 51 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 21 hours 16 minutes ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 6 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 1 day 8 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day 7 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 7 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 2 days 9 hours ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 days 9 hours ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 days 9 hours ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
